Inventor
Stuart Thomas Onions
Inventor
Nottingham, GB
Overview
Patents· 57 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
C07DHeterocyclic compounds30%
A61KPreparations for medical, dental or toiletry purposes24%
C07BGeneral methods of organic chemistry5%
G06FElectric digital data processing3%
G11CStatic stores3%
Y02ATechnologies for adaptation to climate change2%
C07CAcyclic or carbocyclic compounds1%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%
Y10TTechnical subjects covered by former us classification1%
PatentTitleYear
11,001,575Benzolactam compounds as protein kinase inhibitors202110,858,345Process for preparing a compound useful to treat mycoses202010,815,217Inhibitor of p38 MAP kinase202010,813,9321-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors202010,766,861Pharmaceutically active compounds202010,738,0321-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors202010,696,666Pharmaceutical compounds202010,662,179Process for preparing a compound useful to treat mycoses202010,626,126Compounds202010,472,3755,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative201910,457,669Benzolactam compounds as protein kinase inhibitors201910,450,304Compound useful to treat mycoses201910,358,445Respiratory formulations and compounds for use therein201910,344,022Compound useful to treat mycoses201910,336,702Pharmaceutically active compounds201910,294,216Pyrazolyl ureas as kinase inhibitors201910,273,2495,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative201910,266,5191-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors201910,238,6581-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors201910,189,8635,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives201910,160,7725,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives201810,144,721P38 MAP kinase inhibitors201810,118,920Isoxazolyl substituted benzimidazoles201810,106,531Compound useful to treat mycoses201810,045,980Inhibitor of p38 map kinase201810,035,8105,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative201810,000,471Pyrazole P38 map kinase inhibitors20189,993,4781-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors20189,926,335'5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative'20189,884,845'Pyrazolyl-ureas as kinase inhibitors'20189,850,2311-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors20179,771,354'Pyrazole p38 map kinase inhibitors'20179,745,306'2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin-4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors'20179,732,098'5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative'20179,724,347'1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors'20179,701,670'Pyrazolyl-ureas as kinase inhibitors'20179,624,196'Inhibitor of p38 MAP kinase'20179,556,184'Phosphoinositide 3-kinase inhibitors'20179,475,796'1-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors'20169,447,076'Inhibitor of p38 map kinase'20169,260,410'P38 MAP kinase inhibitors'20169,249,125'Pyrazole derivatives as p38 MAP inhibitors'20169,242,960'P38MAP kinase inhibitors'20169,227,977'Phosphoinositide 3-kinase inhibitors'20169,108,950'1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors'20159,024,041'P38 MAP kinase inhibitors'20158,975,285'P38 MAP kinase inhibitors'20158,933,228'Respiratory formulations and compounds for use therein'20158,642,773'P38MAP kinase inhibitor'20148,618,140'P38 MAP kinase inhibitors'20138,299,073'P38 MAP kinase inhibitors'20128,299,074'P38 MAP kinase inhibitors'20128,293,748'p38 MAP kinase inhibitors'20128,293,771'p38 MAP kinase inhibitors'20128,217,050'Adenine derivative as inhibitors of HSP90 for the treatment of cancer'20128,106,091'Inhibitors of IKK-beta serine-threonine protein kinase'20128,003,695'IKK-beta serine-threonine protein kinase inhibitors'2011Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2011–2021Based in Nottingham, GB· patent location history
2012–2020Patents assigned to RESPIVERT LTD (35)· patent assignee history
2012–2018Patents assigned to ONIONS STUART THOMAS (12)· patent assignee history
2012–2018Patents assigned to MURRAY PETER JOHN (11)· patent assignee history
2012–2018Patents assigned to ITO KAZUHIRO (9)· patent assignee history
2017–2020Patents assigned to PULMOCIDE LTD (13)· patent assignee history
2018–2020Based in Nottinghamshire, GB· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| RESPIVERT LTD | 35 | 2012–2020 |
| PULMOCIDE LTD | 13 | 2017–2020 |
| ONIONS STUART THOMASself | 12 | 2012–2018 |
| MURRAY PETER JOHN | 11 | 2012–2018 |
| ITO KAZUHIRO | 9 | 2012–2018 |
Locations
| Location | Patents | Span |
|---|---|---|
| Nottingham, GB | 51 | 2011–2021 |
| Nottinghamshire, GB | 6 | 2018–2020 |